drugset / Trial / NCT04044937
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.
Timeline
- Start
- 2018-10-29
- Primary completion
- 2024-03-31
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FET | Diagnostic / imaging agent | 148 mbq | Intravenous |
| Subject | 18F-FET | Diagnostic / imaging agent | 259 mbq | Intravenous |